Status
Conditions
Treatments
About
Prospective, observational, parallel-group, postmarketing safety surveillance registry in participants treated with Remicade or standard therapy for active or fistulizing Crohn's disease (CD). The follow-up period is up to 5 years. The participants in the standard therapy group may switch over to Remicade any time during the follow-up period
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
At least 18 years of age, of either sex, and of any race.
Must have active or fistulizing CD and must have experienced at least 1 of the following:
Willing to give written informed consent and must be able to adhere to the procedural requirements of the registry.
Must be evaluated for active and inactive (latent) tuberculosis (TB) at the Baseline Visit. TB evaluation will consist of TB history questions (eg, medical history, possible previous contact with TB, TB vaccination history). TB evaluation and TB screening (eg, skin test, chest x-ray) are required when a subject starts treatment with Remicade. In these cases, subjects must be screened for TB within 3 months prior to initiating Remicade treatment.
Exclusion criteria
In addition, subjects will be excluded from treatment with Remicade if any of the criteria listed below are met:
2,662 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal